Form 4: Ovid Therapeutics Director Granted Stock Options

Ovid Therapeutics Director Jeremy M. Levin was granted 957,000 employee stock options with an exercise price of $1.65.

Summary

• Director Jeremy M. Levin of Ovid Therapeutics Inc. was granted 957,000 employee stock options.
• The options have an exercise price of $1.65 per share.
• The earliest transaction date for this grant was February 26, 2026.
• The options will vest in 48 equal monthly installments, commencing on March 20, 2026.
• Vesting is contingent upon Mr. Levin's continued services to the company through each vesting date.
• The expiration date for these options is February 25, 2036.
• Following this transaction, Mr. Levin beneficially owns 957,000 derivative securities (employee stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it aligns the director's long-term interests with the company's performance through equity ownership, which is a standard and generally beneficial compensation practice.

Positives

• The grant of stock options aligns Director Jeremy M. Levin's long-term financial interests with the performance of Ovid Therapeutics Inc.
• Equity compensation can incentivize management to focus on strategies that enhance shareholder value over time.

Negatives

• The options have no immediate cash value and their ultimate value depends on the future stock price exceeding the exercise price.
• Vesting is subject to continued service, meaning the options could be forfeited if Mr. Levin's service terminates before full vesting.

Risks

• The value of the stock options is subject to market fluctuations; if Ovid Therapeutics' stock price does not rise above the $1.65 exercise price, the options may expire worthless.
• There is a risk of forfeiture of unvested options if the reporting person's service to the company ceases.

Future Outlook

The stock options are designed to vest over a 48-month period, commencing in March 2026, which ties the director's future compensation directly to the company's long-term performance and continued service.

Industry Context

StockSavvy.ai notes that equity grants, such as stock options, are a common form of executive and director compensation in the biotechnology and pharmaceutical industries. This practice is widely adopted to align the interests of key personnel with those of shareholders, encouraging long-term value creation.

Comparison to Industry Standards

• StockSavvy.ai observes that granting stock options to directors is a standard practice in the biotechnology sector, similar to compensation structures seen at companies like Biogen Inc. or Amgen Inc., to incentivize long-term commitment and performance.
• The vesting schedule of 48 equal monthly installments is a typical multi-year approach to retain talent and ensure sustained engagement, comparable to industry benchmarks for executive equity awards.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of Director Jeremy M. Levin's interests with long-term shareholder value through equity ownership.

Next Steps

• The granted stock options will begin vesting in 48 equal monthly installments starting March 20, 2026.

Key Dates

Keywords

Ovid Therapeutics, OVID, Jeremy Levin, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant